Johnson & Johnson FY2025: 6% Revenue Growth to $94.2B, Operating Margin Expands to 34.6% Despite STELARA Biosimilar Impact

What happened

Johnson & Johnson reported worldwide sales of $94.2 billion in fiscal 2025, representing 6.0% growth, comprised of 8.4% volume growth, 3.1% negative price impact, and 0.7% positive currency effect. U.S. sales grew 6.9% to $53.8 billion while international sales increased 5.0% to $40.4 billion. Acquisitions and divestitures contributed a net positive 1.1% to growth, primarily from CAPLYTA and Shockwave. However, STELARA's biosimilar-driven sales decline created a 6.2% headwind to worldwide growth. Consolidated earnings before tax reached $32.6 billion (34.6% margin) compared to $16.7 billion (18.8% margin) in 2024. The dramatic margin expansion resulted from multiple factors: a $7.0 billion reversal of previously accrued talc reserves, absence of the prior year's $1.25 billion Yellow Jersey IPR&D charge, and reduced acquisition-related costs. Cost of products sold increased as a percentage of sales due to unfavorable product mix from STELARA's decline and transactional currency headwinds, partially offset by lower acquisition-related inventory step-up charges ($0.1 billion versus $0.4 billion). Selling, marketing and administrative expenses declined as a percentage of sales due to corporate rationalization and leverage, despite increased CAPLYTA-related investment. Research and development spending fell to $14.7 billion (15.6% of sales) from $17.2 billion (19.4% of sales), driven by the absence of prior year IPR&D charges and investment prioritization. The effective tax rate was 17.7% compared to 15.7% in 2024. Net earnings totaled $26.8 billion. Operating cash flow reached $24.5 billion, while capital expenditures were $4.8 billion. The company deployed $12.4 billion in dividends ($5.14 per share, the 63rd consecutive annual increase) and $6.0 billion in share repurchases. Net debt increased to $27.8 billion from $12.1 billion, driven by $9.2 billion in debt issuance to fund the $14.5 billion Intra-Cellular acquisition and general corporate purposes.

Why it matters for investors

The reported margin expansion to 34.6% is heavily influenced by non-recurring items—particularly the $7.0 billion talc reserve reversal and reduced IPR&D charges—making the headline figure an unreliable indicator of underlying operational performance. Stripping out these items reveals a business managing significant portfolio transition pressures. STELARA's 41.3% revenue decline represents a major structural challenge. With U.S. sales falling from over $10 billion in 2024 to approximately $3.8 billion in 2025 due to biosimilar competition, the company lost substantial high-margin revenue. This 6.2% drag on total company growth and 10.4% drag on Innovative Medicine demonstrates the magnitude of the erosion. Management's ability to offset this through Oncology portfolio strength—particularly the 23% growth in DARZALEX and near-doubling of CARVYKTI—is critical to maintaining growth trajectory. However, the company faces further biosimilar exposure with expected OPSUMIT generic competition in 2026 and potential SIMPONI biosimilars. The Medicare Part D redesign introduced a new structural headwind affecting multiple franchises (ERLEADA, IMBRUVICA, INVEGA, OPSUMIT, UPTRAVI, XARELTO, STELARA), creating price pressure beyond traditional competitive dynamics. The combination of biosimilar erosion, Medicare redesign impacts, and unfavorable product mix drove cost of goods sold higher as a percentage of sales despite volume growth. The $14.5 billion Intra-Cellular acquisition and planned Orthopaedics separation signal active portfolio reshaping. The addition of CAPLYTA ($700 million in sales post-acquisition) addresses Neuroscience gaps, while exiting the $9.3 billion Orthopaedics business (growing only 1.1% with restructuring headwinds) suggests capital reallocation toward higher-growth, higher-margin opportunities. The debt-funded acquisition increased leverage materially (net debt nearly tripling), though operating cash flow of $24.5 billion provides ample coverage. Research productivity remains essential given pipeline dependency. New products introduced within the past five years accounted for approximately 25% of 2025 sales, requiring sustained $14.7 billion annual R&D investment to offset exclusivity losses and biosimilar competition. Multiple regulatory approvals and filings across Oncology, Immunology, and Neuroscience demonstrate active pipeline progression.

Key highlights

Innovative Medicine segment income before tax margin expanded to 36.9% from 33.2%, driven by the absence of the prior year's $1.25 billion Yellow Jersey IPR&D charge, litigation income versus expense, and R&D leverage from investment prioritization, partially offset by $0.4 billion in Intra-Cellular and Halda Therapeutics acquisition costs and unfavorable product mix. MedTech segment margin improved to 12.2% from 11.7% despite $0.9 billion in Auris shareholder litigation expense and higher restructuring costs ($0.5 billion versus $0.2 billion), benefiting from $0.2 billion CVR liability reduction related to Abiomed, absence of prior year's $0.5 billion V-Wave IPR&D expense and $0.3 billion Laminar milestone, and $0.2 billion gain on securities sale. The company completed two major restructuring programs: the Orthopaedics franchise restructuring (cumulative $0.8 billion cost, substantially complete in 2025) and the R&D investment prioritization within Innovative Medicine (cumulative $0.6 billion cost, completed Q4 2024). A new Surgery franchise restructuring initiated in 2025 with estimated total costs of $0.9-$1.0 billion is expected to be substantially completed by end of 2026. The Inflation Reduction Act subjected certain products to government-established pricing beginning in 2026 with potential for additional products in future years, while expanded 340B Federal Drug Discount Program interpretation and abuse may negatively impact financial performance. The company operates 63 manufacturing facilities globally, relies on thousands of suppliers, and faces ongoing risks from supply chain disruptions, counterfeit products, and third-party manufacturing dependencies. Approximately 43% of fiscal 2025 sales occurred outside the U.S., with three wholesalers representing 21.8%, 15.5%, and 11.1% of total gross revenues. The company maintains investment grade credit ratings and has access to a $10 billion 364-day credit facility expiring June 2026, with undrawn capacity providing substantial liquidity alongside $19.7 billion in cash and $0.4 billion in marketable securities.

Management commentary

Management stated that new products introduced within the past five years accounted for approximately 25% of 2025 sales, with $14.7 billion invested in research and development reflecting commitment to create life-enhancing innovations. The company emphasized that with Our Credo as the foundation, it believes health is everything, and through expertise in Innovative Medicine and MedTech, it is uniquely positioned to innovate across the full spectrum of healthcare solutions. Regarding the planned Orthopaedics separation announced in October 2025, management indicated the company intends to explore multiple paths to effect the separation with targeted completion within 18 to 24 months after initial announcement, subject to satisfaction of certain conditions including works council consultations, final Board approval, and regulatory approvals. On the IRA Medicare Drug Price Negotiation Program, management disclosed that in July 2023, Janssen Pharmaceuticals filed litigation challenging the constitutionality of the program under the First and Fifth Amendments. While the litigation filed by Janssen and other pharmaceutical companies remains ongoing, CMS has publicly announced maximum fair prices for selected drugs and begun implementing the program. In December 2025, Janssen sought U.S. Supreme Court review of the Third Circuit's majority affirmance of the district court's ruling in favor of the government. Management stated the long-term implications on the business and broader pharmaceutical industry remain uncertain. Management acknowledged that the company maintains a policy restricting direct delivery of product to locations other than the billing location, impacting contract pharmacy transactions involving non-grantee 340B covered entities for most drugs, subject to multiple exceptions. The company stated it will continue to offer 340B discounts to covered entities on all covered outpatient drugs and believes the policy will improve ability to identify inappropriate duplicate discounts and diversion. Regarding STELARA biosimilar competition, management explicitly stated that third parties have filed biologics license applications with the U.S. FDA, European Medicines Agency, and other authorities seeking approval to market biosimilar versions globally, and the company expects continued launches of biosimilar versions globally which will continue to negatively impact sales. Similarly, management disclosed that at least two biosimilars are pursuing regulatory approval for SIMPONI biosimilar in the United States, which would likely result in significant reduction in future sales, and that generic competition for OPSUMIT is expected in 2026, which would likely result in significant reduction in future sales.

What to watch next

Investors should monitor:

• STELARA biosimilar erosion trajectory and ability of Oncology and Immunology portfolio (TREMFYA, DARZALEX, CARVYKTI) to offset continued high-margin revenue loss, with management expecting ongoing global biosimilar launches and U.S. sales having already declined to approximately $3.8 billion from over $10 billion in 2024.

• OPSUMIT generic competition impact beginning in 2026 on the $4.4 billion Pulmonary Hypertension franchise, and potential SIMPONI biosimilar approvals that management states would likely result in significant sales reduction, compounding exclusivity loss pressures.

• Medicare Part D redesign structural impact on pricing across multiple franchises, with management citing negative effects on ERLEADA, IMBRUVICA, INVEGA, OPSUMIT, UPTRAVI, XARELTO, and STELARA, and overall price contributing negative 3.1% to worldwide growth.

• Execution of the planned Orthopaedics separation within the targeted 18-24 month timeframe, including securing works council consultations, final Board approval, and regulatory clearances, and ability to achieve anticipated strategic and financial benefits from the separation.

• Integration and commercial execution of the $14.5 billion Intra-Cellular acquisition (CAPLYTA) within the Neuroscience franchise, and management of the increased debt load with net debt reaching $27.8 billion and total debt of $47.9 billion (37.0% of total capital).

• Progression of regulatory filings and approvals across the pipeline including TECVAYLI for Multiple Myeloma 1-3PLs (MajesTEC-3), TREMFYA indications for ulcerative colitis and Crohn's disease, IMAAVY for myasthenia gravis, and ICOTYDE for psoriasis to sustain the 25% sales contribution from products introduced in the past five years.

This summary is based solely on excerpts from the company's Form 10-K filing.